Ignite Creation Date:
2024-05-06 @ 3:19 PM
Last Modification Date:
2024-10-26 @ 1:47 PM
Study NCT ID:
NCT04598984
Status:
UNKNOWN
Last Update Posted:
2022-08-08
First Post:
2020-10-09
Brief Title:
The Role of Serum Adipokines in Predicting Response to Neoadjuvant Therapy in Patients With Rectal Cancer
Sponsor:
Istanbul Training and Research Hospital
Organization:
Istanbul Training and Research Hospital
Study Overview
Official Title:
The Role of Serum Adipokines in Predicting Response to Neoadjuvant Therapy in Patients With Rectal Cancer
Status:
UNKNOWN
Status Verified Date:
2022-08
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
It has been shown that adipokines resistin leptin adiponectin secreted from adipose tissue and proinflammatory cytokines such as IL-6 TNF-a are associated with the risk of developing colorectal cancer However the role of these factors in predicting clinical response to neoadjuvant therapy in rectal cancers is unknown In this study the role of serum adipokine levels before neoadjuvant therapy in predicting clinical response in patients with rectal cancer is investigated For this purpose blood will be drawn from patients with rectal cancer who will receive neoadjuvant therapy serum adipokines will be studied and clinical response to neoadjuvant therapy will be compared
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None